Japan Inhaled Corticosteroids Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the Japan Inhaled Corticosteroids Market was valued at USD 720 Million in 2025 and is projected to reach USD 980 Million by 2032, growing at a CAGR of approximately 4.5% during 2026–2032.
Japan Inhaled Corticosteroids Market Highlights
| Report Metric | Details |
| Report Name | Japan Inhaled Corticosteroids Market (2026-2032) |
| Market Size 2025 | USD 720 Million |
| Market Size 2032 | USD 980 Million |
| Absolute Growth 2025–2032 | USD 260 Million |
| CAGR 2026–2032 | 4.5% |
| Peak Annual Growth | 5.7% in 2028 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Drug Name/Form, 2025 | Budesonide (51% share) |
| Leading Indication, 2025 | Asthma / COPD (42% share) |
| Leading Dosage Delivery, 2025 | Nebulizer / Inhaler (42% share) |
| Leading Distribution Channel, 2025 | Prescription Outlets (48% share) |
| Fastest-Growing Drug Name/Form | Fluticasone (6.0% CAGR) |
| Fastest-Growing Indication | Long-Term Inflammation (6.1% CAGR) |
| Fastest-Growing Dosage Delivery | DPI (5.8% CAGR) |
| Fastest-Growing Distribution Channel | Hospital Pharmacies (5.5% CAGR) |
| Growing Sector | respiratory health |
| Key End Users | hospitals, outpatient clinics, pharmacies, healthcare providers |
Japan Inhaled Corticosteroids Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
For each year, the table pairs the estimated growth rate with the leading influence on demand, showing how the drivers changed across the period.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | -2.5 | The market faced initial challenges with a decline in demand from healthcare facilities. |
| 2023 | -1.8 | Demand continued to decline as hospitals adjusted to changing treatment protocols. |
| 2024 | 0.7 | Growth resumed as awareness of asthma management improved among patients. |
| 2025 | 4.9 | The introduction of new inhaled corticosteroid formulations boosted market performance. |
| 2026 | 4.8 | Growth is projected to slow as competition increases among existing products in the market. |
| 2027 | 5.0 | Demand is expected to rise again due to heightened focus on chronic respiratory diseases. |
| 2028 | 5.7 | The market will peak with widespread adoption of new delivery methods. |
| 2029 | 4.4 | Growth is expected to slow as market saturation begins to affect new product introductions. |
| 2030 | 4.2 | Demand is likely to continue slowing as the focus shifts to alternative therapies. |
| 2031 | 3.5 | The market will see a further slowdown as patient preferences evolve. |
| 2032 | 3.9 | Growth is projected to pick up again due to renewed interest in asthma management programs. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
Japan Inhaled Corticosteroids Market Synopsis
Inhaled corticosteroids are anti-inflammatory medications used primarily for managing asthma and chronic obstructive pulmonary disease. These drugs are delivered via inhalers or nebulizers, with demand driven by approximately 3.6 million asthma patients in Japan. The Japan Inhaled Corticosteroids Market is expanding due to ongoing initiatives such as the Ministry of Health's asthma management program launched in 2023, which improves patient care and increases the usage of these medications.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing prevalence of asthma and COPD in Japan drives demand for inhaled corticosteroids. | Driver | High | Asthma / COPD |
| The rising preference for DPI devices enhances patient compliance and expands market reach. | Driver | High | DPI |
| Growing awareness of respiratory health among patients creates demand for effective treatments. | Opportunity | High | Asthma / COPD |
| Investment in hospital pharmacies is increasing, improving access to inhaled medications. | Opportunity | High | Hospital Pharmacies |
| Market competition among generic inhaled corticosteroids may limit pricing power for producers. | Restraint | Medium | Budesonide |
| Regulatory changes can delay product approvals, affecting market entry timelines. | Restraint | Medium | Fluticasone |
| High costs associated with clinical trials can deter new entrants from the market. | Challenge | High | Beclomethasone |
| Evolving patient preferences towards alternative therapies may reduce inhaled corticosteroid usage. | Challenge | Medium | Mometasone |
Evaluation of Drivers in Japan Inhaled Corticosteroids Market (2026–2032)
The table below links each growth driver to the segment it affects and the evidence for it.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| The high prevalence of asthma, affecting around 3.6 million patients, increases demand for inhaled corticosteroids. | Asthma / COPD | This large patient base necessitates effective management solutions, driving purchases. |
| DPI devices are preferred for their ease of use, with a growing market share among inhaled medications. | DPI | This shift towards user-friendly devices encourages more patients to adhere to treatment. |
| The National Health Insurance coverage for inhaled corticosteroids ensures affordability for patients. | Budesonide | This financial support leads to higher prescription rates among healthcare providers. |
| The Tokyo region's concentration of asthma patients creates a significant local market for inhaled corticosteroids. | Fluticasone | Healthcare facilities in this area are more likely to stock these medications. |
| The Japanese Society of Allergology's treatment guidelines promote the use of inhaled corticosteroids. | Mometasone | These guidelines influence physicians' prescribing habits, increasing demand. |
Spending rises because the high prevalence of asthma in Japan drives demand for inhaled corticosteroids. The average age of asthma patients is around 50 years, prompting healthcare providers to seek effective management solutions. The preference for DPI devices, which facilitate easier administration, encourages patient compliance. The Tokyo Medical University conducts research on respiratory diseases, focusing on effective treatment options. These elements contribute to a growing market for inhaled medications.
Evaluation of Restraints in Japan Inhaled Corticosteroids Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Market competition from generic inhaled corticosteroids pressures pricing strategies. | Budesonide | This competition can lead to reduced profit margins for producers. |
| Regulatory delays in product approvals can hinder market entry for new treatments. | Fluticasone | Such delays can extend the time before new products reach patients. |
| High clinical trial costs deter investment in new inhaled corticosteroid formulations. | Beclomethasone | This financial barrier limits innovation and product diversity. |
| Evolving patient preferences towards alternative therapies may reduce reliance on inhaled corticosteroids. | Mometasone | Patients may seek newer treatments, impacting traditional medication sales. |
| Limited awareness among patients about the importance of asthma management can affect demand. | Asthma / COPD | This lack of awareness may lead to underutilization of available treatments. |
Japan Inhaled Corticosteroids Market Challenges
Outpatient clinics face rising costs due to fierce competition among inhaled corticosteroid producers, which compresses profit margins by around 15%. Supply chain disruptions hinder suppliers, leading to raw material shortages that can delay production for hospitals by up to six weeks. Buyers, such as hospitals, encounter increased expenses for inhaled medications, raising patient co-pays by 20%, which restricts access to treatments. Regulatory changes from the Japanese Society of Allergology impose compliance costs on suppliers, potentially elevating prices for clinics and limiting their ability to provide necessary care.
Trends in the Japan Inhaled Corticosteroids Market
Four trends stand out in the Japan Inhaled Corticosteroids Market.
- Shift from MDI to DPI: Since 2023, there has been a notable shift from metered-dose inhalers (MDI) to dry powder inhalers (DPI) among patients. This change is driven by the ease of use and better patient compliance associated with DPI devices, which are gaining popularity in hospitals and clinics.
- Transition to Digital Health Solutions: In 2023, healthcare providers began integrating digital health solutions to monitor asthma management. This trend is reflected in the use of mobile applications that track medication adherence, improving patient outcomes and engagement.
- Emergence of Personalized Medicine: The focus on personalized medicine is increasing, with tailored treatment plans for asthma patients becoming more common. The Tokyo Medical University is leading research in this area, aiming to optimise treatment efficacy based on individual patient profiles.
- Increased Collaboration Between Specialties: Since 2023, there has been a rise in collaboration between ENT clinics and pulmonologists for asthma care. This trend improves patient management and ensures comprehensive treatment approaches, reflecting a more integrated healthcare system.
Investment Opportunities in the Japan Inhaled Corticosteroids Market
Several openings in the Japan Inhaled Corticosteroids Market merit attention from investors.
- Growing Need for Asthma Management: With 3.6 million asthma patients in Japan, there is a growing need for effective inhaled corticosteroids. Investing in new formulations can capture this demand, particularly among hospital pharmacies that prioritise effective treatments.
- Expansion of Hospital Pharmacies: Hospital pharmacies are increasingly investing in respiratory health initiatives, with an annual budget of approximately 1 billion yen. Suppliers can partner with these facilities to ensure a steady supply of inhaled corticosteroids.
- Entry into the DPI Market: The rising preference for DPI devices presents an opportunity for manufacturers to innovate. Collaborating with healthcare providers in urban areas can facilitate market entry and improve product visibility.
- Focus on Patient Education Programs: There is a significant opportunity to invest in patient education programs about asthma management. Engaging with the Japanese Pharmaceutical Association can help raise awareness and drive demand for inhaled corticosteroids.
Government Initiatives in the Japan Inhaled Corticosteroids Market
The Medical Care Act of 1948 establishes standards for hospitals and clinics, ensuring they meet necessary requirements for treating respiratory conditions. This law has shaped the healthcare framework, impacting how inhaled corticosteroids are prescribed and managed in clinical settings. The National Health Insurance drug price standard, revised regularly, ensures that inhaled corticosteroids remain accessible and affordable for patients, promoting their widespread use.
The Pharmaceuticals and Medical Devices Agency (PMDA) reviews pharmaceuticals and monitors post-market safety, ensuring that inhaled corticosteroids meet safety and efficacy standards. The Agency for Medical Research and Development (AMED) funds medical research initiatives aimed at improving treatment options for respiratory diseases, supporting innovation in inhaled corticosteroid formulations.
Future Insight of the Japan Inhaled Corticosteroids Market
Clinics will adopt digital inhaler monitoring systems by 2032, improving patient adherence and health outcomes. The Ministry of Health's asthma management programme will streamline care coordination, benefiting both patients and healthcare providers. Advances in DPI technology will simplify medication delivery, making inhalers more user-friendly for patients. With an annual budget of 1 billion yen allocated to respiratory health initiatives, funding will support research and development, driving innovation in treatment options for asthma and COPD.
Market Segmentation Analysis
Japan Inhaled Corticosteroids Market report covers a detailed analysis of the following market segments:
By Drug Name/Form – Budesonide Leads, Fluticasone Expected to Grow Fastest
According to Saurav Kr Singh, Senior Research Analyst at 6Wresearch, the largest drug name/form category in 2025 was Budesonide, at 51% of revenue. Budesonide holds the largest share due to its widespread application among asthma patients, particularly in hospitals and outpatient clinics. Its recognition in treatment guidelines by the Japanese Society of Allergology further cements its leading position in the market. Over 2026–2032, Fluticasone is expected to post the fastest growth, at a CAGR of 6.0%. Fluticasone is experiencing rapid growth as it is commonly prescribed in 100 mcg and 250 mcg inhalers, appealing to a broad patient base seeking effective respiratory management. This increase in prescriptions reflects a strong preference for Fluticasone among healthcare providers, indicating potential for further market expansion. Suppliers should focus on enhancing the distribution of Fluticasone to effectively meet the growing demand.
By Indication – Asthma / COPD Leads, Long-Term Inflammation Expected to Grow Fastest
Asthma / COPD accounted for 42% of the market by indication in 2025. Asthma and COPD are the primary indications for inhaled corticosteroids, addressing the needs of around 3.6 million asthma patients and the 4.3% prevalence of COPD in Japan. The alignment of these conditions with national health initiatives reinforces their strong market presence. Long-Term Inflammation is projected to grow fastest, at a CAGR of 6.1% during 2026–2032. Long-term inflammation is gaining traction as a key focus area, driven by increasing awareness of chronic respiratory conditions. The recent initiative by the Ministry of Health to improve asthma management highlights the importance of addressing long-term inflammation in treatment protocols. Buyers can anticipate a broader selection of products aimed at long-term inflammation as awareness and treatment options expand.
By Dosage Delivery – Nebulizer / Inhaler Leads, DPI Expected to Grow Fastest
Nebulizer / Inhaler took 42% of dosage delivery revenue in 2025, more than any other category. Nebulizers and inhalers dominate the market as the main delivery method for inhaled corticosteroids, catering to the preferences of patients and healthcare providers. Their established use in hospitals and outpatient settings reinforces their leading share in the market. DPI is set to record the highest CAGR in this split, 5.8% over 2026–2032. DPI devices are rapidly gaining popularity due to their ease of use, making them an attractive option for patients seeking convenience in inhalation therapy. The shift towards DPI reflects changing patient preferences and advancements in inhalation technology. Suppliers should invest in DPI technology to meet the growing demand for user-friendly inhalation devices.
By Distribution Channel – Prescription Outlets Lead, Hospital Pharmacies Expected to Grow Fastest
With 48% of distribution channel revenue in 2025, Prescription Outlets was the largest category. Prescription outlets serve as the main distribution channel for inhaled corticosteroids, ensuring that patients receive their medications through healthcare professionals. This channel's importance is underscored by established treatment protocols for asthma and COPD. The quickest growth will come from Hospital Pharmacies, forecast to expand at a CAGR of 5.5% between 2026 and 2032. Hospital pharmacies are witnessing accelerated growth as they provide crucial access to inhaled corticosteroids for patients during hospital stays. Their role is amplified by collaboration among healthcare providers, ensuring effective patient care through these pharmacies. Suppliers should strengthen collaborations with hospital pharmacies to guarantee consistent availability of their products to patients.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- Japan Inhaled Corticosteroids Market Outlook
- Market Size of Japan Inhaled Corticosteroids Market, 2025
- Forecast of Japan Inhaled Corticosteroids Market, 2032
- Historical Data and Forecast of Japan Inhaled Corticosteroids Revenues & Volume for the Period 2022-2032F
- Japan Inhaled Corticosteroids Market Trend Evolution
- Japan Inhaled Corticosteroids Market Drivers and Challenges
- Japan Inhaled Corticosteroids Price Trends
- Japan Inhaled Corticosteroids Porter's Five Forces
- Japan Inhaled Corticosteroids Industry Life Cycle
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Drug Name/Form for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Budesonide for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Fluticasone for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Beclomethasone for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Mometasone for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Indication for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Asthma / COPD for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Long-Term Inflammation for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Allergies / Wheezing for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Nasal / Respiratory for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Dosage Delivery for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Nebulizer / Inhaler for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By DPI for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By MDI for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Nasal Spray / Inhaler for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Distribution Channel for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Prescription Outlets for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Hospital Pharmacies for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By Drugstores for the Period 2022-2032F
- Historical Data and Forecast of Japan Inhaled Corticosteroids Market Revenues & Volume By ENT Clinics for the Period 2022-2032F
- Japan Inhaled Corticosteroids Import Export Trade Statistics
- Market Opportunity Assessment By Drug Name/Form
- Market Opportunity Assessment By Indication
- Market Opportunity Assessment By Dosage Delivery
- Market Opportunity Assessment By Distribution Channel
- Japan Inhaled Corticosteroids Top Companies Market Share
- Japan Inhaled Corticosteroids Competitive Benchmarking By Technical and Operational Parameters
- Japan Inhaled Corticosteroids Company Profiles
- Japan Inhaled Corticosteroids Key Strategic Recommendations
Market Covered
The following segment groups are covered in the report.
By Drug Name/Form
- Budesonide
- Fluticasone
- Beclomethasone
- Mometasone
By Indication
- Asthma / COPD
- Long-Term Inflammation
- Allergies / Wheezing
- Nasal / Respiratory
By Dosage Delivery
- Nebulizer / Inhaler
- DPI
- MDI
- Nasal Spray / Inhaler
By Distribution Channel
- Prescription Outlets
- Hospital Pharmacies
- Drugstores
- ENT Clinics
